Suven Life Sciences completes 100% enrollment in Phase-2b Trial

Suven Life Sciences Limited has completed 100% patient enrollment in its Phase-2b trial of Ropanicant for Major Depressive Disorder ahead of schedule. The randomised, double-blind study across 35 USA sites targets 195 patients. With LPO expected by February 2026 and topline results by May 2026, safety data so far show no significant concerns.